patent expiry

R&D

Sandoz on the future of generics and biosimilars in Europe

At Reuters Pharma Europe, Sandoz' Claire D'Abreu-Hayling explored the promise of the so-called “golden decade” of patent expiry for generics.

News

MSD splits pharma business, hiving off oncology

MSD is separating its cancer and non-cancer pharma operations as it prepares for the looming loss of patent protection for $31bn blockbuster Keytruda.

News

Novartis sheds staff as Entresto patent expiry looms

Novartis will cut 427 jobs this year in the US as it prepares for the loss of market exclusivity for its blockbuster heart failure therapy Entresto.

News

an older man's hand with a pill in his palm

FDA approves first generics of anticoagulant Xarelto

The FDA has approved the first generic versions of Johnson & Johnson's big-selling anticoagulant Xarelto.

News

BMS extends its cost-cutting drive by another $2bn

BMS is extending its bid to cut costs by $1.5bn before the end of this year, backed by 2200 job cuts, adding a target of another $2bn by end-2027.

News

Novartis less exposed to US pricing pressure, says Jimenez

Europe and Asia account for a large share of company's income.

Sandoz on the future of generics and biosimilars in Europe

MSD splits pharma business, hiving off oncology

Novartis sheds staff as Entresto patent expiry looms

FDA approves first generics of anticoagulant Xarelto

BMS extends its cost-cutting drive by another $2bn

Novartis less exposed to US pricing pressure, says Jimenez

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

patent expiry

Editor's Picks